ЛИТЕРАТУРА к ГЛАВЕ -2 (Вакцинация)

1. Derived from McIntosh EDG, Booy R. Invasive pneumococcal diseases in England and Wales: what is the true burden and what is the potential for prevention using 7-valent pneumococcal conjugate vaccine? Arch Dis Child 2002; 86:403-406.
2. Chief Medical Officer, DoH. Preventing Meningitis; http://www.dh.gov.uk/AboutUs/MinistersAndDepartmentLeaders/ ChiefMedicalOfficer/ProgressOnPolicy/ProgressBrowsableDocument/ fs/en?CONTENT_ID=4102788&MULTIPAGE_ID=5389535& chk=Uq8NtA
3. Ispahani P et al. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch Dis Child 2004; 89: 757-762.
4. Baraff L et al. Outcomes of bacterial meningitis in children: a meta-analysis. Paed Infect Dis J 1993; 12:389-394.
5. Drummond P et al. Community acquired pneumonia - a prospective UK study. Arch Dis Child 2000; 83:408-412.
6. Djuretic T et al. Hospital admissions in children due to pneumococcal pneumonia in England. J Infect 1998; 37:54-58 
7. Miller E et al. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998. Acta Paed Suppl 2000; 435: 11-16
8. Bedford H et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001; 323: 1-5.
9. Eskola et al. Efficacy of pneumococcal conjugate vaccine against acute otitis media. NEJM 2001; 344: 403-409.
10. Black S et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. PIDJ 2000; 19: 187-195.
11. Rovers MM et al. Otitis Media. Lancet 2004; 363: 465-73
12. NICE. Referral practice: A guide to appropriate referral from general to specialist practice. Pg. 34.
13. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical Practice Guideline: Management of Sinusitis. Paediatrics 2001; 108: 798-808.
14. Prodigy guidance - sinusitis. http://www.prodigy.nhs.uk . Accessed Dec Jan 2006.
15. McIntosh D et al. McIntosh et al. How many episodes of hospital care might be prevented by widespread uptake of 7 valent pneumococcal conjugate vaccine? Arch Dis Child 2003; 88: 859-861.
16. Levine et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Paediatrics 1999; 103: 1-5.
17. Dagan R et al. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. PIDJ 2001; 20:951-958
18. Dagan R et al. Modelling the association between pneumococcal carriage and child care-centre attendance. CID 2005;
19. Givon-Lavi et al. Spread of Streptococcus pneumoniae and antibiotic-resistant Streptococcus pneumoniae from day-care centre attendees to their younger siblings. JID 2002; 186: 000.
20. Grant et al. Invasive pneumococcal disease in Oxford 1985-2001: a retrospective case series. Arch Dis Child 2003; 88: 712-714.
21. Giebink S. The prevention of pneumococcal disease in children. NEJM 2001; 345: 1177-1182.
22. Hussain et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epid Inf 2005; 133: 891-898.
23. Derived from Miller E et al. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998. Acta Paediatr Suppl 2000; 435: 1-16
24. Saez-Llorens X et al. Bacterial meningitis in children. Lancet 2003; 361: 2139-2148.
25. JCVI meeting minutes. www.advisorybodies.doh.gov.uk/jcvi/mins011004.htm .
26. CMO Letter. http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=SS_GET_PAGE &siteId=en&ssTargetNodeId=612&ssDocName=DH_4137171
27. CMO letter, March 2005. http://www.dh.gov.uk/assetRoot/04/10/79/12/04107912.pdf